Apollon  CGM Secures Innovation Award at CES 2025

Apollon recently bagged the prestigious CES 2025 Innovation Award in the ‘Digital Health’ category. This post dives into why Apollon’s recognition matters for health tech and what this means for you and the broader market.

Apollon CGM’s Innovation: The Moglu Device

The Moglu device sets itself apart by providing continuous glucose monitoring (CGM) without invasive procedures.

Key Features of Moglu:

• Detects glucose using Raman signals.
• Compact wearable design.
• Jointly developed with MIT.

Apollon’s collaboration with MIT has played a pivotal role in developing Moglu. Their expertise helped miniaturize the device, paving the way for its current testing at MIT’s clinical center on general participants.

CES Innovation Award: Significance and Trends

CES Innovation Awards, hosted by the Consumer Technology Association, highlight groundbreaking tech products. The criteria have become more stringent, reducing the number of awarded products.

Recent Trends in CES Awards:

• Digital Health Focus: Only 13% of total awards went to digital health in 2025, reflecting growing selectivity.
• Historical Data:
  • 86 awards in 2023.
  • 56 awards in 2024.
  • 47 awards in 2025.

In the CGM sector, Apollon stands among giants like Abbott and Dexcom, being one of the few worldwide to receive this recognition.

Implications for the Market and Consumers

Apollon’s innovation highlights the potential shift in how glucose levels are monitored. Here’s how this affects you:

• For CGM Users: Less invasive monitoring methods are becoming accessible.
• For the Industry: Increased emphasis on miniaturization and accuracy.
• For Innovators: Raises the bar for what constitutes groundbreaking tech.

Future Plans and Development

Apollon’s CEO, Hong Aram, stressed their commitment to further research and development. Using clinical results, they aim:

1. Device Minimization: Further reduce size to below that of a smartphone.
2. Clinical Trials: Begin patient-specific trials at Harvard Medical School’s Joslin Diabetes Center by late next year.

Apollon’s Research Team and Strategy

Apollon’s U.S. division, with Ph.D.-level researchers, focuses on optical system advancements. In Korea, the team handles circuit design and software, crucial for creating cutting-edge compact devices.

Areas of Expertise:

• Optical system optimization.
• Circuit design.
• Advanced software development.

Such comprehensive efforts underline their strategy to maintain and enhance cutting-edge health tech.

The Bigger Picture: Health Tech Evolution

Apollon’s award at CES underscores broader trends in health technology:

• Increasing Demand: Rising interest in non-invasive devices.
• International Collaboration: Institutions like MIT enhance credibility and innovation.
• Stricter Benchmarks: Survival of the fittest as award conditions tighten.

Apollon’s Continued Efforts and Recognition

Their receipt of the award alongside industry leaders reinforces their potential in the global arena.

Related Recognitions:

• Future Unicorn Award by LG during Super Start Day.
• 23 Billion Pre-Series A Investment: Underscores investor confidence in their non-invasive CGM solutions.

Apollon leverages high-profile collaborations and continues to expand its technological frontier, marking a significant milestone in digital health.

Conclusion

Apollon’s achievement at CES reflects a broader shift toward innovative, non-invasive health solutions. Keep an eye on Apollon CGM—they’re leading the charge in transforming diabetes care and wearable tech. This recognition is not just an award but a signal of their potential to redefine CGM and health monitoring.

Table of Contents:

1. Introduction
   • Overview of Apollon’s Achievement
   • Importance of the CES Innovation Award
2. Apollon’s Innovation: The Moglu Device
   • Features and Benefits of Moglu
   • Collaboration with MIT
3. CES Innovation Award: Significance and Trends
   • Criteria for the Awards
   • Trends in Digital Health Recognition
4. Implications for the Market and Consumers
   • Insights for CGM Users
   • Industry Impact
   • Opportunities for Innovators
5. Future Plans and Development
   • Commitment to R&D
   • Upcoming Clinical Trials
6. Apollon’s Research Team and Strategy
   • Structure of the U.S. and Korea Teams
   • Areas of Expertise
7. The Bigger Picture: Health Tech Evolution
   • Demand for Non-Invasive Devices
   • Importance of International Collaboration
   • Stricter Award Benchmarks
8. Apollon’s Continued Efforts and Recognition
   • Additional Awards and Recognition
   • Investor Confidence and Future Prospects
9. Conclusion
   • Summary of Apollon’s Impact on Health Tech
   • Future Outlook for Diabetes Care and Wearable Technology